FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Country

Document

No Title 0.59 MB
Registration Date 30 Aug 2022
Revision Date 30 Aug 2022
Share

Adynovate

(0)

Medicine Pharmaceuticals

Coagulation Modifier

Drug Information

Generic
antihemophilic factor (recombinant) pegylated
Drug Class
Coagulation Modifiers
Therapeutic Class
Blood Modifiers
Dosage form
Powder
Route of Administration
Intravenous Injection
Therapeutic Area
1.Anti-Hemophilic

Nanomaterials

Manufacturer Asserted

Polymeric Nanoparticle

Nanoparticle /Nanopowder

Benefit

Adynovate, is a recombinant pegylated anti-hemophilic factor used for treatment of hemophilia A in patients who experience repeated bleeding events. Adynovate works by increasing levels of blood-clotting factor VIII in the blood in a temporary manner. Adynovate has an extended circulation time in the human body leading to reduced frequency of injection. The structure comprises coagulation factor VIII conjugated to PEG. Some common side effects include diarrhea, nausea, headache, vomiting, rash and other common allergic reactions.